12. November 2009 11:00
Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) announced today that Catherine Taylor, one of the Company's funded researchers, will be presenting pre-clinical stability and biological activity data on SNS-01, Senesco's multiple myeloma drug candidate, at the 2009 American Association for Cancer Research (AACR)-National Cancer Institute (NCI)-European Organization for Research and Treatment of Cancer (EORTC) Molecular Targets and Cancer Therapeutics Conference. Ms. Taylor is a member of the Department of Biology at the University of Waterloo, Ontario, Canada. The conference will take place from Sunday, November 15th through Thursday, November 19th, in Boston, MA. Ms. Taylor's abstract will be presented at a session entitled, "Gene Therapies", which will run from 12:30 PM until 2:30 PM on Monday, November 16th.
The conference, hosted by AACR, NCI and EORTC, will bring together academics and scientists and representatives from the pharmaceutical industry to discuss innovation in drug development, target selection and the impact of new discoveries in molecular and cell biology. The event has been organized to reflect the many recent advances in the early development of promising new compounds, which are in different levels of preclinical and clinical development.
SOURCE Senesco Technologies, Inc.
Subscribe